Severe Complications of Chicken Pox in Hospitalized Children in the UK and Ireland
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Severe Complications of Chicken Pox in Hospitalized Children in the UK and Ireland

LONDON, U.K. -- November 9, 2007 -- The only realistic way of preventing deaths and severe complications arising from chickenpox is to routinely vaccinate children against the disease, concludes research published ahead of print in Archives of Disease in Childhood.

At present, only healthcare workers and others likely to be at risk of contracting or passing on the infection, are routinely immunised in the UK. But vaccination programmes for children have been introduced in several other countries, including the USA, Canada, Australia, and Finland.

The authors base their conclusions on active monitoring by paediatricians in the UK and Ireland of children up to the age of 16 admitted to hospital with severe complications resulting from chickenpox infection.

During the monitoring period, which ran for 13 months between 2002 and 2003, 188 cases were reported to the British Paediatric Surveillance Unit.

Of these, 112 children met the criteria, giving a case rate of 0.82 per 100,000. Their average age was 3 years.

The complications included septic shock, pneumonia, and encephalitis, as well as uncoordinated movement (ataxia), toxic shock syndrome, and "flesh eating" bacterial infection (necrotising fasciitis).

Almost half the children (46%) had additional bacterial infections.

Six children died. One child died in the womb. Although four of the five other children, who were aged between 2 and 14 years, already had a pre-existing medical condition, these were not groups currently targeted for immunisation.

After discharge, 4 out of 10 children had ongoing problems as a result of their infection, including, most commonly, ataxia or skin scarring.

Their average length of hospital stay was seven days, but ranged from one to 68.

Most of these children were healthy before they contracted the virus, say the authors. Universal immunisation could have prevented their complications, as they were mostly old enough to have received the vaccine.

An accompanying editorial in the journal comments: "Chickenpox has traditionally been viewed as an irritating but inevitable infection to be endured during childhood, a rite of passage during the preschool years."

"This benign view persists despite evidence that certain groups, including neonates, adults, pregnant women, and the immunocompromised have higher risks of severe disease," it continues.

The authors point out that new cases of chickenpox have been rising among pre-school children, and for every 1000 cases, between two and five children will have to be admitted to hospital.

The simplest strategy would be to switch from the triple MMR vaccine to one that also included immunity against chickenpox (varicella), using the recently licensed MMRV jab, say the authors. But unfounded fears about MMR are likely make this difficult to implement at present. But varicella vaccine could be offered to all teenagers who have not yet been infected.

"This could prevent cases of severe disease in adults and pregnant women and raise public awareness of the potential and desirability of primary prevention," they conclude.

SOURCE: British Medical Journal

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities